Science 37, Crinetics and Gritstone Bio announce inducement grants to boost talent acquisition

[ipopba/Adobe Stock]

Science 37 Holdings (Nasdaq:SNCE), Crinetics Pharmaceuticals (Nasdaq: CRNX) and Gritstone Bio (Nasdaq:GRTS) have announced recent inducement grants to attract new non-executive employees under Nasdaq Listing Rule 5635(c)(4). This move showcases the companies’ focus on talent acquisition and retention in the competitive pharmaceutical and biotechnology markets.

A clinical trial research organization based in Durham, North Carolina, Science 37 announced today that its compensation committee signed off on inducement equity awards. In all, the company granted options to purchase an aggregate of 110,800 shares of its common stock at an exercise price of $0.29 per share to three new employees. The options have a 10-year term and a four-year vesting schedule.

Grants for Critics and Gritstone

The clinical-stage pharma firm Crinetics Pharmaceuticals specializing in rare endocrine disease…

Read more
  • 0

Novel COVID-19 vaccine could offer broad immune responses across SARS-CoV-2 variants

The emerging biotech Gritstone Bio (NSDQ:GRTS) has dosed the first patient with its second-generation COVID-19 vaccine known as GRT-R910. The University of Manchester and Manchester University NHS Foundation Trust are jointly overseeing the U.K.-based Phase 1 study.

The GRT-R910 vaccine uses self-amplifying mRNA (SAM), which could optimize antigen expression at lower doses relative to conventional mRNA. The GRT-R910 vaccine targets antigens from the spike protein and highly conserved non-spike proteins on the SARS-CoV-2 virus.

Emeryville, California–based Gritstone believes the vaccine could offer a strong and durable immune response to various SARS-CoV-2 variants. It may also eliminate the need for repeat boosters, the company concluded.

The company believes that the technology will outperform the first generation of mRNA COVID-19 vaccines in those 60 and older.

“Our SAM COVID vaccine is designed to drive robust CD8+ T cell responses, in addition…

Read more
  • 0